Meta-Analysis of Prognostic Factors for Recurrence of Resected Well-Differentiated Pancreatic Neuroendocrine Tumors

被引:16
作者
Li, Yuanliang [1 ,2 ]
Fan, Guohui [3 ]
Yu, Fuhuan [1 ,2 ]
Tian, Chao [1 ,2 ]
Tan, Huangying [2 ]
机构
[1] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China
[2] China Japan Friendship Hosp, Dept Integrat Oncol, 2 Yinghuadong Rd, Beijing 100029, Peoples R China
[3] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing, Peoples R China
基金
国家重点研发计划;
关键词
Pancreatic neuroendocrine tumor; Recurrence; Prognostic factors; SURGICAL-MANAGEMENT; LIVER METASTASES; ADJUVANT THERAPY; NEOPLASMS; SURVIVAL;
D O I
10.1159/000514047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Well-differentiated pancreatic neuroendocrine tumors (WDPNETs) are a group of rare and heterogeneous tumors. However, the prognostic factors for recurrence after curative resection still remain controversial. We aim to illustrate the prognostic factors for recurrence of resected WDPNETs. Methods: All relevant articles published through June 2020 were identified via PubMed, Embase, Web of Science, and Cochrane Library. Articles that examined the prognostic factors of WDPNETs were enrolled. Results: Ten articles were finally included in this study. From 1993 to 2018, 2,863 patients underwent curative resection and 358 patients had recurrence, and the combined recurrence rate was 13%. Furthermore, the pooled data indicated that patients with G2, positive lymph node and surgical resection margin, vascular invasion, and perineural invasion had a decreased disease-free survival for WDPNETs. However, gender, function, and tumor size had no significant relationship with WDPNETs recurrence. Conclusion: These findings demonstrated that G2, positive lymph node and surgical resection margin, vascular invasion, and perineural invasion could be prognostic factors for recurrence of resected WDPNETs, indicating that patients with these high-risk factors need closer postoperative follow-up and may benefit from adjuvant therapy.
引用
收藏
页码:1231 / 1237
页数:7
相关论文
共 28 条
[1]  
[Anonymous], 2017, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, V4th
[2]   Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study [J].
Ausania, F. ;
Senra del Rio, P. ;
Gomez-Bravo, M. A. ;
Martin-Perez, E. ;
Perez-Daga, J. A. ;
Dorcaratto, D. ;
Gonzalez-Nicolas, T. ;
Sanchez-Cabus, S. ;
Tardio-Baiges, A. .
PANCREATOLOGY, 2019, 19 (02) :367-371
[3]   Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit [J].
Barrett, James R. ;
Rendell, Victoria ;
Pokrzywa, Courtney ;
Lopez-Aguiar, Alexandra G. ;
Cannon, John ;
Poultsides, George A. ;
Rocha, Flavio ;
Crown, Angelena ;
Beal, Eliza ;
Michael Pawlik, Timothy ;
Fields, Ryan ;
Panni, Roheena Z. ;
Smith, Paula ;
Idrees, Kamran ;
Cho, Clifford ;
Beems, Megan ;
Maithel, Shishir ;
Weber, Sharon ;
Erik Abbott, Daniel .
JOURNAL OF SURGICAL ONCOLOGY, 2020, 121 (07) :1067-1073
[4]   Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment [J].
Baur, Alexander D. J. ;
Pavel, Marianne ;
Prasad, Vikas ;
Denecke, Timm .
ACTA RADIOLOGICA, 2016, 57 (03) :260-270
[5]   Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States [J].
Dasari, Arvind ;
Shen, Chan ;
Halperin, Daniel ;
Zhao, Bo ;
Zhou, Shouhao ;
Xu, Ying ;
Shih, Tina ;
Yao, James C. .
JAMA ONCOLOGY, 2017, 3 (10) :1335-1342
[6]   Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases [J].
Dong, Ding-Hui ;
Zhang, Xu-Feng ;
Poultsides, George ;
Rocha, Flavio ;
Weber, Sharon ;
Fields, Ryan ;
Idrees, Kamran ;
Cho, Cliff ;
Maithel, Shishir K. ;
Pawlik, Timothy M. ;
Lopez-Aguiar, Alexandra G. ;
Makris, Eleftherios ;
Kanji, Zaheer ;
Fisher, Alexander ;
Krasnick, Bradley A. ;
Smith, Paula M. ;
Beems, Megan ;
Dillhoff, Mary .
JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (07) :1071-1079
[7]   ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors [J].
Falconi, M. ;
Eriksson, B. ;
Kaltsas, G. ;
Bartsch, D. K. ;
Capdevila, J. ;
Caplin, M. ;
Kos-Kudla, B. ;
Kwekkeboom, D. ;
Rindi, G. ;
Kloeppel, G. ;
Reed, N. ;
Kianmanesh, R. ;
Jensen, R. T. .
NEUROENDOCRINOLOGY, 2016, 103 (02) :153-171
[8]   Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to 68Ga-DOTATOC PET [J].
Flechsig, Paul ;
Zechmann, Christian M. ;
Schreiweis, Julian ;
Kratochwil, Clemens ;
Rath, Daniel ;
Schwartz, Lawrence H. ;
Schlemmer, Heinz-Peter ;
Kauczor, Hans-Ulrich ;
Haberkorn, Uwe ;
Giesel, Frederik L. .
EUROPEAN JOURNAL OF RADIOLOGY, 2015, 84 (08) :1593-1600
[9]   Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67 [J].
Genc, C. G. ;
Falconi, M. ;
Partelli, S. ;
Muffatti, F. ;
van Eeden, S. ;
Doglioni, C. ;
Klumpen, H. J. ;
van Eijck, C. H. J. ;
van Dijkum, E. J. M. Nieveen .
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (08) :2467-2474
[10]   Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data [J].
Gordon-Dseagu, Vanessa L. ;
Devesa, Susan S. ;
Goggins, Michael ;
Stolzenberg-Solomon, Rachael .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2018, 47 (02) :427-439